Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo

Journal of the National Cancer Institute

Volumn 91, Issue 14, 1999, Pages 1233-1241

  Aghi, Manish ^c   Kramm, Christof M ^b   Breakefield, Xandra O ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

EDATREXATE; FOLIC ACID ANTAGONIST; FOLYLPOLYGLUTAMATE SYNTHASE; METHOTREXATE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG DELIVERY SYSTEM; ENZYME BINDING; GENE TRANSFER; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 0033591840     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.14.1233     Document Type: Article

References (46)

1. Chu E, Allegra C. Antifolates. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy: principles and practice. Philadelphia (PA): Lippincott-Raven; 1996. p. 109-48.
2. Balinska M, Galivan J, Coward JK. Efflux of methotrexate and its polyglutamate derivatives from hepatic cells in vitro. Cancer Res 1981; 41:2751-6.
3. Pizzorno G, Mini E, Coronnello M, McGuire JJ, Moroson BA, Cashmore AR, et al. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug. Cancer Res 1988;48:2149-55.
4. Roy K, Mitsugi K, Sirlin S, Shane B, Sirotnak FM. Different antifolate-resistant L1210 cell variants with either increased or decreased folylpolyglutamate synthetase gene expression at the level of mRNA transcription. J Biol Chem 1995;270:26918-22.
5. Roy K, Egan MG, Sirlin S, Sirotnak FM. Post-transcriptionally mediated decreases in folylpolyglutamate synthetase gene expression in some folate analogue-resistant variants of the L1210 cell. Evidence for an altered cognate mRNA in the variants affecting the rate of de novo synthesis of the enzyme. J Biol Chem 1997;272:6903-8.
6. Takemura Y, Kobayashi H, Miyachi H, Furihata K. Altered expression of folylpolyglutamate synthetase (FPGS) gene in human leukemia cells with defective polyglutamation of raltitrexed (ZD1694) [abstract]. Br J Cancer 1997;75(suppl 1):31.
7. Rodenhuis S, McGuire JJ, Narayanan R, Bertino JR. Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells. Cancer Res 1986;46:6513-9.
8. Li WW, Lin JT, long WP, Trippett TM, Brennan MF, Bertino JR. Mechanisms of natural resistance to antifolates in human soft tissue sarcomas. Cancer Res 1992;52:1434-8.
9. Rumberger BG, Barrueco JR, Sirotnak FM. Differing specificities for 4-aminofolate analogues of folylpolyglutamyl synthetase from tumors and proliferative intestinal epithelium of the mouse with significance for selective antitumor action. Cancer Res 1990;50: 4639-43.
10. Kim JS, Lowe KE, Shane B. Regulation of folate and one-carbon metabolism in mammalian cells. IV. Role of folylpoly-gammaglutamate synthetase in methotrexate metabolism and cytotoxicity. J Biol Chem 1993;268: 21680-5.
11. Sirotnak FM, DeGraw JI, Moccio DM, Samuels LL, Goutas LJ. New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. Cancer Chemother Pharmacol 1984;12:18-25.
12. 10-propargyl-5,8-dideazofolic acid and related compounds. J Med Chem 1989;32: 1284-9.
13. Rosowsky A, Bader H, Cucchi CA, Moran RG, Kohler W, Freisheim JH. Methotrexate analogues. 33. N-δ-Acyl-Nα-(4-amino-4-deoxypteroyl)-L-ornithine derivatives: synthesis and in vitro antitumor activity. J Med Chem 1988;31:1332-7.
14. Fraefel C, Song S, Lim F, Lang P, Yu L, Wang Y, et al. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 1996;70:7190-7.
15. Weizsaecker M, Deen DF, Rosenblum ML, Hoshino T, Gutin PH, Barker M. The 9L rat brain tumor: description and application of an animal model. J Neurol 1981;224:183-92.
16. Scharf JM, Boviatsis EJ, Fleet C, Breakefield XO, Chiocca EA. Genetically modified rat 9L gliosarcoma cells facilitate detection of infiltrating tumor cells in a rat model of brain neoplasms. Transgenics 1994;1:219-24.
17. Ponten J, Macintyre EH. Long term culture of normal and neoplastic human glia. Acta Pathol Microbiol Scand 1968;74:465-86.
18. Benda P, Lightbody J, Sato G, Levine L, Sweet W. Differentiated rat glial cell strain in tissue culture. Science 1968;161:370-1.
19. Zhu D, Caveney S, Kidder GM, Naus CC. Transfection of C6 glioma cells with connexin 43 cDNA: analysis of expression, intercellular coupling, and cell proliferation. Proc Natl Acad Sci U S A 1991;88:1883-7.
20. Aghi M, Kramm CM, Chou TC, Breakefield XO, Chiocca EA. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst 1998;90:370-80.
21. Marquardt DW. An algorithm for least square estimate of non-linear parameters. SIAM J Appl Math 1963;11:431-41.
22. Friedlos F, Denny WA, Palmer BD, Springer CJ. Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy. J Med Chem 1997;40: 1270-5.
23. Price J, Turner D, Cepko C. Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc Natl Acad Sci U S A 1987;84:156-60.
24. Cunningham C, Davison AJ. A cosmid-based system for constructing mutants of herpes simplex virus type 1. Virology 1993;197:116-24.
25. Egan MG, Sirlin S, Rumberger BG, Garrow TA, Shane B, Sirotnak FM. Rapid decline in folylpolyglutamate synthetase activity and gene expression during maturation of HL-60 cells. Nature of the effect, impact on folate compound polyglutamate pools, and evidence for programmed down-regulation during maturation. J Biol Chem 1995;270:5462-8.
26. Wright JE, Rosowsky A, Waxman DJ, Trites D, Cucchi CA, Flatow J, et al. Metabolism of methotrexate and γ-tert-butyl methotrexate by human leukemic cells in culture and by hepatic aldehyde oxidase in vitro. Biochem Pharmacol 1987;36:2209-14.
27. Ellenberger TE, Wright JE, Rosowsky A, Beverley SM. Wild-type and drug-resistant Leishmania major hydrolyze methotrexate to N-10-methyl-4-deoxy-4-aminopteroate without accumulation of methotrexate polyglutamates. J Biol Chem 1989;264:15960-6.
28. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977;297:630-4.
29. Inaba M, Kobayashi T, Tashiro T, Sakurai Y, Maruo K, Ohnishi Y, et al. Evaluation of anti-tumor activity in a human breast tumor/nude mouse model with a special emphasis on treatment dose. Cancer 1989;64:1577-82.
30. Peters GJ, van der Wilt CL, Cloos J, Pinedo HM. Development of a simple folylpolyglutamate synthetase assay in tissues and cell lines. Adv Exp Med Biol 1993;338:651-4.
31. Manome Y, Wen PY, Dong Y, Tanaka T, Mitchell BS, Kufe DW, et al. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat Med 1996;2:567-73.
32. Moran RG, Colman PD, Jones TR. Relative substrate activities of structurally related pteridine, quinazoline, and pyrimidine analogs for mouse liver folylpolyglutamate synthetase. Mol Pharmacol 1989;36:736-43.
33. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53:5274-83.
34. Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A 1994;91: 8302-6.
35. Fry DW, Anderson LA, Borst M, Goldman ID. Analysis of the role of membrane transport and polyglutamation of methotrexate in gut and the Ehrlich tumor in vivo as factors in drug sensitivity and selectivity. Cancer Res 1983;43: 1087-92.
36. Matherly LH, Barlowe CK, Goldman ID. Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells. Cancer Res 1986;46:588-93.
37. Black ME, Newcomb TG, Wilson HM, Loeb LA. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl Acad Sci U S A 1996;93: 3525-9.
38. Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997;3:1354-61.
39. Dong Y, Wen P, Manome Y, Parr M, Hirshowitz A, Chen L, et al. In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Hum Gene Ther 1996;7:713-20.
40. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997;89:21-39.
41. Shapiro WR. High-dose methotrexate in malignant gliomas. Cancer Treat Rep 1977;61: 753-6.
42. Terzis AJ, Fiskerstrand T, Refsum H, Ueland PM, Arnold H, Bjerkvig R. Proliferation, migration, and invasion of human glioma cells exposed to antifolate drugs. Int J Cancer 1993; 54:112-8.
43. Cher L, Glass J, Harsh GR, Hochberg FH. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology 1996;46:1757-9.
44. Yamada K, Ushio Y, Hayakawa T, Kato A, Yamada N, Mogami H. Quantitative autoradiographic measurements of blood-brain barrier permeability in the rat glioma model. J Neurosurg 1982;57:394-8.
45. Neuwelt EA, Barnett PA, McCormick CI, Frenkel EP, Minna JD. Osmotic blood-brain barrier modification: monoclonal antibody, albumin, and methotrexate delivery to cerebro-spinal fluid and brain. Neurosurgery 1985;17: 419-23.
46. Inamura T, Nomura T, Bartus RT, Black KL. Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. J Neurosurg 1994;81:752-8.